Thomas Jefferson University

Jean Hoffman-Censits

TitleAssoc Prof CHP
InstitutionThomas Jefferson University
DepartmentNursing - Undergraduate
Address1025 Walnut St.
Philadelphia PA 19107
Phone215-503-6413
vCardDownload vCard

    Collapse Overview 
    Collapse overview
    GU malignancies

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Baraban EG, Vlachou E, Patel S, Kates M, Johnson B, Smith A, Shenderov E, Sharma S, Denmeade SR, Brame A, Han M, De Marzo AM, Matoso A, Hoffman-Censits J. Nectin-4 Expression in Prostatic Adenocarcinoma: An Immunohistochemical Study. Prostate. 2025 Jan 02. PMID: 39748460.
      Citations:    
    2. Mishra A, Sharma AK, Gupta K, Banka DR, Johnson BA, Hoffman-Censits J, Huang P, McConkey DJ, Nimmagadda S. NECTIN-4 PET FOR OPTIMIZING ENFORTUMAB VEDOTIN DOSE-RESPONSE IN UROTHELIAL CARCINOMA. bioRxiv. 2024 Dec 25. PMID: 39763905.
      Citations:    
    3. Geynisman DM, Abbosh PH, Ross E, Zibelman MR, Ghatalia P, Anari F, Mark JR, Stamatakis L, Hoffman-Censits JH, Viterbo R, Greenberg RE, Churilla TM, Horwitz EM, Hallman MA, Smaldone MC, Uzzo R, Chen DYT, Kutikov A, Plimack ER. Phase II Trial of Risk-Enabled Therapy After Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer (RETAIN 1). J Clin Oncol. 2024 Dec 16; JCO2401214. PMID: 39680823.
      Citations:    
    4. Vlachou E, Johnson BA, Hoffman-Censits J. The Role of Antibody-Drug Conjugates in Urothelial Cancer: A Review of Recent Advances in the Treatment of Locally Advanced and Metastatic Urothelial Cancer. Clin Med Insights Oncol. 2024; 18:11795549241290787. PMID: 39686979.
      Citations:    
    5. Rosenberg JE, Galsky MD, Powles T, Petrylak DP, Bellmunt J, Loriot Y, Necchi A, Hoffman-Censits J, Perez-Gracia JL, van der Heijden MS, Dreicer R, Dur?n I, Castellano D, Drakaki A, Retz M, Sridhar SS, Grivas P, Yu EY, O'Donnell PH, Burris HA, Mariathasan S, Shi Y, Goluboff E, Bajorin D. Atezolizumab monotherapy for metastatic urothelial carcinoma: final analysis from the phase II IMvigor210 trial. ESMO Open. 2024 Dec; 9(12):103972. PMID: 39642637.
      Citations:    
    6. Vlachou E, Hoffman-Censits J, Singla N. The biologic landscape and therapeutic implications of upper tract urothelial cancer. Curr Opin Urol. 2024 Oct 14. PMID: 39436198.
      Citations:    
    7. Apolo AB, Ballman KV, Sonpavde G, Berg S, Kim WY, Parikh R, Teo MY, Sweis RF, Geynisman DM, Grivas P, Chatta G, Reichert ZR, Kim JW, Bilen MA, McGregor B, Singh P, Tripathi A, Cole S, Simon N, Niglio S, Ley L, Cordes L, Srinivas S, Huang J, Odegaard M, Watt C, Petrylak D, Hoffman-Censits J, Wen Y, Hahn O, Mitchell C, Tan A, Streicher H, Sharon E, Moon H, Woods M, Halabi S, Perez Burbano G, Morris MJ, Rosenberg JE. Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma. N Engl J Med. 2024 Sep 15. PMID: 39282902.
      Citations:    
    8. Kao CJ, Charmsaz S, Alden SL, Brancati M, Li HL, Balaji A, Munjal K, Howe K, Mitchell S, Leatherman J, Griffin E, Nakazawa M, Tsai HL, Danilova L, Thoburn C, Gizzi J, Gross NE, Hernandez A, Coyne EM, Shin SM, Babu JS, Apostol GW, Durham J, Christmas BJ, Konig MF, Lipson EJ, Naidoo J, Cappelli LC, Pabani A, Ged Y, Baretti M, Brahmer J, Hoffman-Censits J, Seiwert TY, Garonce-Hediger R, Guha A, Bansal S, Tang L, Jaffee EM, Chandler GS, Mohindra R, Ho WJ, Yarchoan M. Immune-related events in individuals with solid tumors on immunotherapy associate with Th17 and Th2 signatures. J Clin Invest. 2024 Aug 29; 134(20). PMID: 39403935.
      Citations:    
    9. Johnson Iii BA, Teply BA, Kagemann C, McGuire B, Lombardo K, Jing Y, Langbo W, Epstein JI, Netto GJ, Baras AS, Matoso A, McConkey DJ, Gupta A, Ahuja N, Ross AE, Pierorazio PM, Comperat E, Hoffman-Censits J, Singla N, Patel SH, Kates M, Choi W, Bivalacqua TJ, Hahn NM. Neoadjuvant Cisplatin, Gemcitabine, and Docetaxel in Sarcomatoid Bladder Cancer: Clinical Activity and Whole Transcriptome Analysis. Bladder Cancer. 2024; 10(2):133-143. PMID: 39131872.
      Citations:    
    10. Vlachou E, Johnson BA, McConkey D, Jing Y, Matoso A, Hahn NM, Hoffman-Censits J. Enfortumab vedotin-related cutaneous toxicity correlates with overall survival in patients with urothelial cancer: a retrospective experience. Front Oncol. 2024; 14:1377842. PMID: 38933451.
      Citations:    
    11. Satyal U, Valentine H, Liu D, Slifker M, Lallas CD, Trabulsi EJ, Bukavina L, Szeto L, Hoffman-Censits JH, Mouw KW, Faltas BM, Grivas P, Ibragimova I, Porten SP, Van Allen EM, Geynisman DM, Parker DC, O'Neill JP, Drevik J, Christianson SS, Ginzburg S, Correa AF, Uzzo RG, Ross EA, Zibelman MR, Ghatalia P, Plimack ER, Kutikov A, Abbosh PH. Urine Biopsy as Dynamic Biomarker to Enhance Clinical Staging of Bladder Cancer in Radical Cystectomy Candidates. JCO Precis Oncol. 2024 Jun; 8:e2300362. PMID: 38865671.
      Citations:    
    12. Vlachou E, Johnson ? BA, Guancial E, Lombardo KA, Hoffman-Censits J. Frontline immune checkpoint inhibitors in patients = 90 years with advanced urothelial cancer: a single center experience. Can J Urol. 2024 Jun; 31(3):11875-11879. PMID: 38912939.
      Citations:    
    13. Vlachou E, Johnson BA, Baraban E, Nadal R, Hoffman-Censits J. Current Advances in the Management of Nonurothelial Subtypes of Bladder Cancer. Am Soc Clin Oncol Educ Book. 2024 Jun; 44(3):e438640. PMID: 38870453.
      Citations:    
    14. Flaig TW, Spiess PE, Abern M, Agarwal N, Bangs R, Buyyounouski MK, Chan K, Chang SS, Chang P, Friedlander T, Greenberg RE, Guru KA, Herr HW, Hoffman-Censits J, Kaimakliotis H, Kishan AU, Kundu S, Lele SM, Mamtani R, Mian OY, Michalski J, Montgomery JS, Parikh M, Patterson A, Peyton C, Plimack ER, Preston MA, Richards K, Sexton WJ, Siefker-Radtke AO, Stewart T, Sundi D, Tollefson M, Tward J, Wright JL, Cassara CJ, Gurski LA. NCCN Guidelines? Insights: Bladder Cancer, Version 3.2024. J Natl Compr Canc Netw. 2024 05; 22(4):216-225. PMID: 38754471.
      Citations:    
    15. Vlachou E, Mamtani R, Hahn NM, Iii BJ, Hoffman-Censits J, Nimgaonkar V. Racial Differences in Cutaneous Events Among Patients Receiving Enfortumab Vedotin. Clin Genitourin Cancer. 2024 Jun; 22(3):102090. PMID: 38688798.
      Citations:    
    16. Powles T, Valderrama BP, Gupta S, Bedke J, Kikuchi E, Hoffman-Censits J, Iyer G, Vulsteke C, Park SH, Shin SJ, Castellano D, Fornarini G, Li JR, G?m?s M, Mar N, Loriot Y, Fl?chon A, Duran I, Drakaki A, Narayanan S, Yu X, Gorla S, Homet Moreno B, van der Heijden MS. Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer. N Engl J Med. 2024 Mar 07; 390(10):875-888. PMID: 38446675.
      Citations:    
    17. Fletcher SA, Pallauf M, Watts EK, Lombardo KA, Campbell JA, Rezaee ME, Roupr?t M, Boorjian SA, Potretzke AM, Roshandel MR, Ploussard G, Djaladat H, Ghoreifi A, Mari A, Campi R, Khene ZE, Raman JD, Kikuchi E, Rink M, Abdollah F, Boormans JL, Fujita K, D'Andrea D, Soria F, Breda A, Hoffman-Censits J, McConkey DJ, Shariat SF, Pradere B, Singla N. Oncologic Outcomes in Patients with Residual Upper Tract Urothelial Carcinoma Following Neoadjuvant Chemotherapy. Eur Urol Oncol. 2024 Jan 22. PMID: 38262800.
      Citations:    
    18. Oldan JD, Schroeder JA, Hoffman-Censits J, Rathmell WK, Milowsky MI, Solnes LB, Nimmagadda S, Gorin MA, Khandani AH, Rowe SP. PET/Computed Tomography Transformation of Oncology: Kidney and Urinary Tract Cancers. PET Clin. 2024 Jan 09. PMID: 38199916.
      Citations:    
    19. Liao RS, Ruan HT, Jang A, Huynh M, Nadal Rios R, Hoffman-Censits JH, Wei S, Mian OY, Barata PC. Emerging Insights in Small-Cell Carcinoma of the Genitourinary Tract: From Diagnosis to Novel Therapeutic Horizons. Am Soc Clin Oncol Educ Book. 2024 Jan; 44:e430336. PMID: 38176691.
      Citations:    
    20. Feng M, Matoso A, Epstein G, Fong M, Park YH, Gabrielson A, Patel S, Czerniak B, Comp?rat E, Hoffman-Censits J, Kates M, Kim S, McConkey D, Choi W. Reply to Kentaro Inamura's Letter to the Editor re: Mingxiao Feng, Andres Matoso, Gabriel Epstein, et al. Identification of Lineage-specific Transcriptional Factor-defined Molecular Subtypes in Small Cell Bladder Cancer. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2023.05.023. Eur Urol. 2023 Sep 27. PMID: 37775361.
      Citations:    
    21. Hoffman-Censits J, Grivas P, Powles T, Hawley J, Tyroller K, Seeberger S, Guenther S, Jacob N, Mehr KT, Hahn NM. The JAVELIN Bladder Medley trial: avelumab-based combinations as first-line maintenance in advanced urothelial carcinoma. Future Oncol. 2023 Sep 06. PMID: 37671748.
      Citations:    
    22. Doroshow DB, O'Donnell PH, Hoffman-Censits JH, Gupta SV, Vaishampayan U, Heath EI, Garcia P, Zhao Q, Yu M, Milowsky MI, Galsky MD. Phase II Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations. JCO Precis Oncol. 2023 Jul; 7:e2300095. PMID: 37410974.
      Citations:    
    23. Feng M, Matoso A, Epstein G, Fong M, Park YH, Gabrielson A, Patel S, Czerniak B, Comp?rat E, Hoffman-Censits J, Kates M, Kim S, McConkey D, Choi W. Identification of Lineage-specific Transcriptional Factor-defined Molecular Subtypes in Small Cell Bladder Cancer. Eur Urol. 2023 Jun 27. PMID: 37380560.
      Citations:    
    24. Mark JR, Gomella LG, Lallas CD, Smentkowski KE, Calvaresi A, Handley N, Den RB, Mille P, Tester WJ, Hoffman-Censits J, Dicker AP, Klonicke E, Halpern E, McCue P, Kelly WK, Trabulsi EJ. Enhancing bladder cancer care through the multidisciplinary clinic approach. Can J Urol. 2023 06; 30(3):11526-11531. PMID: 37344462.
      Citations:    
    25. Agrawal P, Rostom M, Alam R, Florissi I, Biles M, Rodriguez K, Hahn NM, Johnson BA, Matoso A, Smith A, Bivalacqua TJ, Kates M, Hoffman-Censits J, Patel SH. Clinicopathologic and Survival After Cystectomy Outcomes in Squamous Cell Carcinoma of the Bladder. Clin Genitourin Cancer. 2023 May 30. PMID: 37336703.
      Citations:    
    26. Coleman JA, Clark PE, Bixler BR, Buckley DI, Chang SS, Chou R, Hoffman-Censits J, Kulkarni GS, Matin SF, Pierorazio PM, Potretzke AM, Psutka SP, Raman JD, Smith AB, Smith L. Diagnosis and Management of Non-Metastatic Upper Tract Urothelial Carcinoma: AUA/SUO Guideline. J Urol. 2023 Apr 25; 101097JU0000000000003480. PMID: 37096584.
      Citations:    
    27. Parimi V, Choi W, Feng M, Fong M, Hoffman-Censits J, Kates M, Lombardo KA, Comperat E, McConkey DJ, Hahn NM, Esteves RS, Matoso A. Comparison of Clinicopathological Characteristics, Gene Expression Profiles, Mutational Analysis, and Clinical Outcomes of Pure and Mixed Small Cell Carcinoma of the Bladder. Histopathology. 2023 Feb 08. PMID: 36754853.
      Citations:    
    28. Vlachou E, Matoso A, McConkey D, Jing Y, Johnson BA, Hahn NM, Hoffman-Censits J. Enfortumab Vedotin-related Cutaneous Toxicity and Radiographic Response in Patients with Urothelial Cancer: A Single-center Experience and Review of the Literature. Eur Urol Open Sci. 2023 Mar; 49:100-103. PMID: 36820243.
      Citations:    
    29. Hoffman-Censits J, Maldonado L. Targeted Treatment of Locally Advanced and Metastatic Urothelial Cancer: Enfortumab Vedotin in Context. Onco Targets Ther. 2022; 15:1519-1529. PMID: 36545447.
      Citations:    
    30. Flaig TW, Spiess PE, Abern M, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Chan K, Chang S, Friedlander T, Greenberg RE, Guru KA, Herr HW, Hoffman-Censits J, Kishan A, Kundu S, Lele SM, Mamtani R, Margulis V, Mian OY, Michalski J, Montgomery JS, Nandagopal L, Pagliaro LC, Parikh M, Patterson A, Plimack ER, Pohar KS, Preston MA, Richards K, Sexton WJ, Siefker-Radtke AO, Tollefson M, Tward J, Wright JL, Dwyer MA, Cassara CJ, Gurski LA. NCCN Guidelines? Insights: Bladder Cancer, Version 2.2022. J Natl Compr Canc Netw. 2022 08; 20(8):866-878. PMID: 35948037.
      Citations:    
    31. Pal SK, Somford DM, Grivas P, Sridhar SS, Gupta S, Bellmunt J, Sonpavde G, Fleming MT, Lerner SP, Loriot Y, Hoffman-Censits J, Valderrama BP, Andresen C, Schnabel MJ, Cole S, Daneshmand S. Targeting FGFR3 alterations with adjuvant infigratinib in invasive urothelial carcinoma: the phase III PROOF 302 trial. Future Oncol. 2022 May 24. PMID: 35608106.
      Citations:    
    32. Gabrielson AT, Daniels MJ, Rowe J, Alam R, Lee EJ, Matoso A, De Felice A, Hahn N, Hoffman-Censits J, Bivalacqua TJ, Kates M. Residual CIS after neoadjuvant chemotherapy and radical cystectomy for muscle invasive bladder cancer: Implications for neoadjuvant trials. Urol Oncol. 2022 Jan 16. PMID: 35045949.
      Citations:    
    33. Patel SH, Wang S, Metcalf MR, Gupta N, Gabrielson A, Lee E, Rostom M, Pierorazio P, Smith A, Hahn N, Schoenberg M, Kates M, Hoffman-Censits J, Bivalacqua TJ. Safety and Efficacy of Reproductive Organ-Sparing Radical Cystectomy in Women With Variant Histology and Advanced Stage. Clin Genitourin Cancer. 2022 Feb; 20(1):60-68. PMID: 34896022.
      Citations:    
    34. Choi W, Lombardo K, Patel S, Epstein G, Feng M, Gabrielson A, Hahn NM, Hoffman-Censits J, McConkey D, Bivalacqua TJ, Matoso A, Kates M. A Molecular Inquiry into the Role of Antibody-Drug Conjugates in Bacillus Calmette-Guérin-exposed Non-muscle-invasive Bladder Cancer. Eur Urol. 2022 Feb; 81(2):138-142. PMID: 34736796.
      Citations:    
    35. Lyou Y, Rosenberg JE, Hoffman-Censits J, Quinn DI, Petrylak D, Galsky M, Vaishampayan U, De Giorgi U, Gupta S, Burris H, Rearden J, Li A, Xu C, Andresen C, Moran S, Daneshmand S, Bajorin D, Pal SK, Grivas P. Infigratinib in Early-Line and Salvage Therapy for FGFR3-Altered Metastatic Urothelial Carcinoma. Clin Genitourin Cancer. 2022 Feb; 20(1):35-42. PMID: 34782263.
      Citations:    
    36. Patel HD, Patel SH, Blanco-Martinez E, Kuzbel J, Chen VS, Druck A, Koehne EL, Patel PM, Doshi CP, Hahn NM, Hoffman-Censits JH, Berg S, Bivalacqua TJ, Kates M, Quek ML. Four versus 3 Cycles of Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: Implications for Pathological Response and Survival. J Urol. 2021 Aug 27; 101097JU0000000000002189. PMID: 34445890.
      Citations:    
    37. Aragaki AK, Jing Y, Hoffman-Censits J, Choi W, Hahn NM, Trock BJ, McConkey DJ, Johnson BA. Gender-specific Stratification of Survival Following Immune Checkpoint Inhibitor Therapy Based on Intratumoral Expression of a B cell Gene Signature. Eur Urol Oncol. 2021 Aug 20. PMID: 34426176.
      Citations:    
    38. Ghandour RA, Freifeld Y, Cheaib J, Singla N, Meng X, Kenigsberg A, Bagrodia A, Woldu S, Hoffman-Censits J, Enikeev D, Rapoport L, Petros FG, Raman JD, Pierorazio PM, Matin SF, Margulis V. Predictive model for systemic recurrence following cisplatin-based neoadjuvant chemotherapy and radical nephroureterectomy for high risk upper tract urothelial carcinoma. Urol Oncol. 2021 Nov; 39(11):788.e15-788.e21. PMID: 34330655.
      Citations:    
    39. Hoffman-Censits J, Lombardo K, McConkey D, Hahn NM, Bashir B, Kelly WK, Johnson B, Matoso A. New and topics: enfortumab vedotin mechanisms of response and resistance in urothelial cancer - What do we understand so far? Urol Oncol. 2021 10; 39(10):619-622. PMID: 34148797.
      Citations:    
    40. McConkey DJ, Singla N, Pierorazio P, Lombardo K, Matoso A, Hoffman-Censits J. Molecular subtypes of upper tract urothelial cancer: Setting the stage for precision therapy. Cancer Cell. 2021 Jun 14; 39(6):745-747. PMID: 34129819.
      Citations:    
    41. Hoffman-Censits J, Kanesvaran R, Bangs R, Fashoyin-Aje L, Weinstock C. Breaking Barriers: Addressing Issues of Inequality in Trial Enrollment and Clinical Outcomes for Patients With Kidney and Bladder Cancer. Am Soc Clin Oncol Educ Book. 2021 Jun; 41:e174-e181. PMID: 34061566.
      Citations:    
    42. Wang S, Metcalf M, Hoffman-Censits J, Bivalacqua T, Patel SH. Penile sarcomatoid urothelial carcinoma: A case report. Urol Case Rep. 2021 Sep; 38:101706. PMID: 34703768.
      Citations:    
    43. Hoffman-Censits JH, Lombardo KA, Parimi V, Kamanda S, Choi W, Hahn NM, McConkey DJ, McGuire BM, Bivalacqua TJ, Kates M, Matoso A. Expression of Nectin-4 in Bladder Urothelial Carcinoma, in Morphologic Variants, and Nonurothelial Histotypes. Appl Immunohistochem Mol Morphol. 2021 Apr 23. PMID: 33901032.
      Citations:    
    44. Thakur ML, Tripathi SK, Gomella LG, Salmanoglu E, Kim S, Kelly WK, Keith SW, Intenzo C, McCue P, Hoffman-Censits J, Trabulsi EJ. Imaging urothelial bladder cancer: A VPAC PET targeted approach. Can J Urol. 2021 Apr; 28(2):10596-10602. PMID: 33872557.
      Citations:    
    45. Bellmunt J, Hussain M, Gschwend JE, Albers P, Oudard S, Castellano D, Daneshmand S, Nishiyama H, Majchrowicz M, Degaonkar V, Shi Y, Mariathasan S, Grivas P, Drakaki A, O'Donnell PH, Rosenberg JE, Geynisman DM, Petrylak DP, Hoffman-Censits J, Bedke J, Kalebasty AR, Zakharia Y, van der Heijden MS, Sternberg CN, Davarpanah NN, Powles T. Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2021 04; 22(4):525-537. PMID: 33721560.
      Citations:    
    46. Börcsök J, Sztupinszki Z, Bekele R, Gao SP, Diossy M, Samant AS, Dillon KM, Tisza V, Spisák S, Rusz O, Csabai I, Pappot H, Frazier ZJ, Konieczkowski DJ, Liu D, Vasani N, Rodrigues JA, Solit DB, Hoffman-Censits JH, Plimack ER, Rosenberg JE, Lazaro JB, Taplin ME, Iyer G, Brunak S, Lozsa R, Van Allen EM, Szüts D, Mouw KW, Szallasi Z. Identification of a synthetic lethal relationship between nucleotide excision repair (NER) deficiency and irofulven sensitivity in urothelial cancer. Clin Cancer Res. 2020 Nov 18. PMID: 33208343.
      Citations:    
    47. Hoffman-Censits J, Choi W, Bivalacqua TJ, Pierorazio P, Kates M, Lombardo K, Parini V, McConkey D, Trabulsi EJ, Hahn N, Matoso A. Small Cell Bladder Cancer Response to Second-line and Beyond Checkpoint Inhibitor Therapy: Retrospective Experience. Clin Genitourin Cancer. 2020 Nov 12. PMID: 33358150.
      Citations:    
    48. Bedke J, Merseburger AS, Loriot Y, Castellano D, Choy E, Duran I, Rosenberg JE, Petrylak DP, Dreicer R, Perez-Gracia JL, Hoffman-Censits JH, Van Der Heijden MS, Pavlova J, Thiebach L, de Ducla S, Fear S, Powles T, Sternberg CN. Partial Response and Stable Disease Correlate with Positive Outcomes in Atezolizumab-treated Patients with Advanced Urinary Tract Carcinoma. Eur Urol Focus. 2020 Nov 06. PMID: 33168461.
      Citations:    
    49. Cheaib JG, Claus LE, Patel HD, Kates MR, Matoso A, Hahn NM, Bivalacqua TJ, Hoffman-Censits JH, Pierorazio PM. Site of metastatic recurrence impacts prognosis in patients with high-grade upper tract urothelial carcinoma. Urol Oncol. 2021 Jan; 39(1):74.e9-74.e16. PMID: 33071108.
      Citations:    
    50. Lombardo KA, Murati Amador B, Parimi V, Hoffman-Censits J, Choi W, Hahn NM, Kates M, Bivalacqua TJ, McConkey D, Hoque MO, Matoso A. Urothelial Carcinoma In Situ of the Bladder: Correlation of CK20 Expression With Adaptive Immune Resistance, Response to BCG Therapy, and Clinical Outcome. Appl Immunohistochem Mol Morphol. 2020 Aug 28. PMID: 32858539.
      Citations:    
    51. Gupta N, Rasmussen SEVP, Haney N, Smith A, Pierorazio PM, Johnson MH, Hoffman-Censits J, Bivalacqua TJ. Understanding psychosocial and sexual health concerns among women with bladder cancer undergoing radical cystectomy. Urology. 2020 Aug 24. PMID: 32853645.
      Citations:    
    52. Lyou Y, Grivas P, Rosenberg JE, Hoffman-Censits J, Quinn DI, Petrylak DP, Galsky M, Vaishampayan U, De Giorgi U, Gupta S, Burris H, Rearden J, Li A, Wang H, Reyes M, Moran S, Daneshmand S, Bajorin D, Pal SK. Hyperphosphatemia Secondary to the Selective Fibroblast Growth Factor Receptor 1-3 Inhibitor Infigratinib (BGJ398) Is Associated with Antitumor Efficacy in Fibroblast Growth Factor Receptor 3-altered Advanced/Metastatic Urothelial Carcinoma. Eur Urol. 2020 Aug 23. PMID: 32847703.
      Citations:    
    53. Becker REN, Meyer AR, Brant A, Reese AC, Biles MJ, Harris KT, Netto G, Matoso A, Hoffman-Censits J, Hahn NM, Choi W, McConkey D, Pierorazio PM, Johnson MH, Schoenberg MP, Kates MR, Baras A, Bivalacqua TJ. Clinical Restaging and Tumor Sequencing are Inaccurate Indicators of Response to Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer. Eur Urol. 2020 Aug 17. PMID: 32814637.
      Citations:    
    54. Lee CT, Mohamed NE, Pisipati S, Shah QN, Agarwal PK, Downs TM, Droller M, Gilbert SM, Goltz HH, Hall SJ, Hendawi M, Hoffman-Censits J, O'Donnell M, Kaag M, Karsh LI, Kassouf W, Quale DZ, Sagalowsky A, Steinberg GD, Latini DM. Development and evaluation of a bladder Cancer specific survivorship care plan by patients and clinical care providers: a multi-methods approach. BMC Health Serv Res. 2020 Jul 24; 20(1):686. PMID: 32709234.
      Citations:    
    55. Hoffman-Censits J, Pal S, Kaiser C, Ding B, Bellmunt J. Atezolizumab in patients with renal insufficiency and mixed variant histology: analyses from an expanded access program in platinum-treated locally advanced or metastatic urothelial carcinoma. J Immunother Cancer. 2020 Jul; 8(2). PMID: 32641319.
      Citations:    
    56. Pal SK, Bajorin D, Dizman N, Hoffman-Censits J, Quinn DI, Petrylak DP, Galsky MD, Vaishampayan U, De Giorgi U, Gupta S, Burris HA, Soifer HS, Li G, Wang H, Dambkowski CL, Moran S, Daneshmand S, Rosenberg JE. Infigratinib in upper tract urothelial carcinoma versus urothelial carcinoma of the bladder and its association with comprehensive genomic profiling and/or cell-free DNA results. Cancer. 2020 Mar 24. PMID: 32208524.
      Citations:    
    57. Miron B, Hoffman-Censits JH, Anari F, O'Neill J, Geynisman DM, Zibelman MR, Kutikov A, Viterbo R, Greenberg RE, Chen D, Lallas CD, Trabulsi EJ, Alpaugh RK, Dulaimi E, Golemis EA, Uzzo R, Ross EA, Plimack ER. Defects in DNA Repair Genes Confer Improved Long-term Survival after Cisplatin-based Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer. Eur Urol Oncol. 2020 Mar 10. PMID: 32165095.
      Citations:    
    58. Flaig TW, Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Chang S, Downs TM, Efstathiou JA, Friedlander T, Greenberg RE, Guru KA, Guzzo T, Herr HW, Hoffman-Censits J, Hoimes C, Inman BA, Jimbo M, Kader AK, Lele SM, Michalski J, Montgomery JS, Nandagopal L, Pagliaro LC, Pal SK, Patterson A, Plimack ER, Pohar KS, Preston MA, Sexton WJ, Siefker-Radtke AO, Tward J, Wright JL, Gurski LA, Johnson-Chilla A. Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2020 03; 18(3):329-354. PMID: 32135513.
      Citations:    
    59. Hoffman-Censits J, Choi W, Pal S, Trabulsi E, Kelly WK, Hahn NM, McConkey D, Comperat E, Matoso A, Cussenot O, Cancel-Tassin G, Fong MHY, Ross J, Madison R, Ali S. Urothelial Cancers with Small Cell Variant Histology Have Confirmed High Tumor Mutational Burden, Frequent TP53 and RB Mutations, and a Unique Gene Expression Profile. Eur Urol Oncol. 2020 Feb 12. PMID: 32061548.
      Citations:    
    60. Lin J, Den RB, Greenspan J, Showalter TN, Hoffman-Censits JH, Lallas CD, Trabulsi EJ, Gomella LG, Hurwitz MD, Leiby B, Dicker AP, Kelly WK. Phase I Trial of Weekly Cabazitaxel with Concurrent Intensity Modulated Radiation and Androgen Deprivation Therapy for the Treatment of High-Risk Prostate Cancer. Int J Radiat Oncol Biol Phys. 2020 Feb 03. PMID: 32029346.
      Citations:    
    61. Margulis V, Puligandla M, Trabulsi EJ, Plimack ER, Kessler ER, Matin SF, Godoy G, Alva A, Hahn NM, Carducci MA, Hoffman-Censits J. Reply by Authors. J Urol. 2020 Jan 22; 101097JU000000000000064402. PMID: 31967495.
      Citations:    
    62. Margulis V, Puligandla M, Trabulsi EJ, Plimack ER, Kessler ER, Matin SF, Godoy G, Alva A, Hahn NM, Carducci MA, Hoffman-Censits J. Phase II Trial of Neoadjuvant Systemic Chemotherapy Followed by Extirpative Surgery for Patients with High Grade Upper Tract Urothelial Carcinoma. J Urol. 2019 Nov 08; 101097JU0000000000000644. PMID: 31702432.
      Citations:    
    63. Lin J, Song AJ, Hoffman-Censits J, Leiby BE, Tuluc M, Shaw C, Harshyne L, Kean R, Bar-Ad V, Den RB, Hurwitz MD, Louie J, Philipose S, Deshmukh SP, Johnson JM, Dicker AP, Hooper DC, Kelly WK, Lu B. A Pilot Study of Radiation Therapy in Combination With Pembrolizumab in Patients With Metastatic Renal Cell Cancer. Am J Clin Oncol. 2019 Nov 05. PMID: 31693508.
      Citations:    
    64. Anari F, O'Neill J, Choi W, Chen DYT, Haseebuddin M, Kutikov A, Dulaimi E, Alpaugh RK, Devarajan K, Greenberg RE, Bilusic M, Wong YN, Viterbo R, Hoffman-Censits JH, Lallas CD, Trabulsi EJ, Smaldone M, Geynisman DM, Zibelman M, Lin J, Kelly WK, Uzzo R, McConkey D, Plimack ER. Neoadjuvant Dose-dense Gemcitabine and Cisplatin in Muscle-invasive Bladder Cancer: Results of a Phase 2 Trial. Eur Urol Oncol. 2018 May; 1(1):54-60. PMID: 30420974.
      Citations:    
    65. Pal SK, Rosenberg JE, Hoffman-Censits JH, Berger R, Quinn DI, Galsky MD, Wolf J, Dittrich C, Keam B, Delord JP, Schellens JHM, Gravis G, Medioni J, Maroto P, Sriuranpong V, Charoentum C, Burris HA, Grünwald V, Petrylak D, Vaishampayan U, Gez E, De Giorgi U, Lee JL, Voortman J, Gupta S, Sharma S, Mortazavi A, Vaughn DJ, Isaacs R, Parker K, Chen X, Yu K, Porter D, Graus Porta D, Bajorin DF. Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with FGFR3 Alterations. Cancer Discov. 2018 Jul; 8(7):812-821. PMID: 29848605.
      Citations:    
    66. Rosenberg JE, Hahn NM, Regan MM, Werner L, Alva A, George S, Picus J, Alter R, Balar A, Hoffman-Censits J, Grivas P, Lauer R, Guancial EA, Hoimes C, Sonpavde G, Albany C, Stein MN, Breen T, Jacobs C, Anderson K, Bellmunt J, Lalani AA, Pal S, Choueiri TK. Apatorsen plus docetaxel versus docetaxel alone in platinum-resistant metastatic urothelial carcinoma (Borealis-2). Br J Cancer. 2018 May 16. PMID: 29765151.
      Citations:    
    67. Pal SK, Hoffman-Censits J, Zheng H, Kaiser C, Tayama D, Bellmunt J. Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Clinical Experience from an Expanded Access Study in the United States. Eur Urol. 2018 Feb 22. PMID: 29478735.
      Citations:    
    68. Godwin JL, Hoffman-Censits J, Plimack E. Recent developments in the treatment of advanced bladder cancer. Urol Oncol. 2018 Mar; 36(3):109-114. PMID: 29395952.
      Citations:    
    69. Liu D, Abbosh P, Keliher D, Reardon B, Miao D, Mouw K, Weiner-Taylor A, Wankowicz S, Han G, Teo MY, Cipolla C, Kim J, Iyer G, Al-Ahmadie H, Dulaimi E, Chen DYT, Alpaugh RK, Hoffman-Censits J, Garraway LA, Getz G, Carter SL, Bellmunt J, Plimack ER, Rosenberg JE, Van Allen EM. Mutational patterns in chemotherapy resistant muscle-invasive bladder cancer. Nat Commun. 2017 Dec 19; 8(1):2193. PMID: 29259186.
      Citations:    
    70. Giri VN, Knudsen KE, Kelly WK, Abida W, Andriole GL, Bangma CH, Bekelman JE, Benson MC, Blanco A, Burnett A, Catalona WJ, Cooney KA, Cooperberg M, Crawford DE, Den RB, Dicker AP, Eggener S, Fleshner N, Freedman ML, Hamdy FC, Hoffman-Censits J, Hurwitz MD, Hyatt C, Isaacs WB, Kane CJ, Kantoff P, Karnes RJ, Karsh LI, Klein EA, Lin DW, Loughlin KR, Lu-Yao G, Malkowicz SB, Mann MJ, Mark JR, McCue PA, Miner MM, Morgan T, Moul JW, Myers RE, Nielsen SM, Obeid E, Pavlovich CP, Peiper SC, Penson DF, Petrylak D, Pettaway CA, Pilarski R, Pinto PA, Poage W, Raj GV, Rebbeck TR, Robson ME, Rosenberg MT, Sandler H, Sartor O, Schaeffer E, Schwartz GF, Shahin MS, Shore ND, Shuch B, Soule HR, Tomlins SA, Trabulsi EJ, Uzzo R, Vander Griend DJ, Walsh PC, Weil CJ, Wender R, Gomella LG. Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017. J Clin Oncol. 2018 Feb 01; 36(4):414-424. PMID: 29236593.
      Citations:    
    71. Harshman LC, Tripathi A, Kaag M, Efstathiou JA, Apolo AB, Hoffman-Censits JH, Stadler WM, Yu EY, Bochner BH, Skinner EC, Downs T, Kiltie AE, Bajorin DF, Guru K, Shipley WU, Steinberg GD, Hahn NM, Sridhar SS. Contemporary Patterns of Multidisciplinary Care in Patients With Muscle-invasive Bladder Cancer. Clin Genitourin Cancer. 2017 Dec 06. PMID: 29289519.
      Citations:    
    72. Wilde L, Mehrotra P, Hoffman-Censits J. Recurrent renal cell carcinoma presenting as a solitary left ventricular mass. Can J Urol. 2017 Dec; 24(6):9145-9147. PMID: 29260644.
      Citations:    
    73. Necchi A, Joseph RW, Loriot Y, Hoffman-Censits J, Perez-Gracia JL, Petrylak DP, Derleth CL, Tayama D, Zhu Q, Ding B, Kaiser C, Rosenberg JE. Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: post-progression outcomes from the phase II IMvigor210 study. Ann Oncol. 2017 Dec 01; 28(12):3044-3050. PMID: 28950298.
      Citations:    
    74. Valicenti RK, Pugh SL, Trabulsi EJ, Sartor O, Ko EC, Girvigian MR, Rosenthal SA, Shaves ME, Hoffman-Censits JH, Schallenkamp J, Sandler HM. First Report of NRG Oncology/Radiation Therapy Oncology Group 0622: A Phase 2 Trial of Samarium-153 Followed by Salvage Prostatic Fossa Irradiation in High-Risk Clinically Nonmetastatic Prostate Cancer After Radical Prostatectomy. Int J Radiat Oncol Biol Phys. 2018 Mar 01; 100(3):695-701. PMID: 29413282.
      Citations:    
    75. Patel SA, Hoffman-Censits J. Cabazitaxel in the treatment of metastatic castration-resistant prostate cancer: patient selection and special considerations. Onco Targets Ther. 2017; 10:4089-4098. PMID: 28860817.
      Citations:    
    76. Wilde L, Ali SM, Solomides CC, Ross JS, Trabulsi E, Hoffman-Censits J. Response to Pembrolizumab in a Patient With Chemotherapy Refractory Bladder Cancer With Small Cell Variant Histology: A Case Report and Review of the Literature. Clin Genitourin Cancer. 2017 Jun; 15(3):e521-e524. PMID: 28143711.
      Citations:    
    77. Balar AV, Galsky MD, Rosenberg JE, Powles T, Petrylak DP, Bellmunt J, Loriot Y, Necchi A, Hoffman-Censits J, Perez-Gracia JL, Dawson NA, van der Heijden MS, Dreicer R, Srinivas S, Retz MM, Joseph RW, Drakaki A, Vaishampayan UN, Sridhar SS, Quinn DI, Durán I, Shaffer DR, Eigl BJ, Grivas PD, Yu EY, Li S, Kadel EE, Boyd Z, Bourgon R, Hegde PS, Mariathasan S, Thåström A, Abidoye OO, Fine GD, Bajorin DF. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet. 2017 01 07; 389(10064):67-76. PMID: 27939400.
      Citations:    
    78. Hoffman-Censits J, Wilde L. Combination immunotherapy in genitourinary malignancies. Curr Opin Urol. 2016 Nov; 26(6):523-8. PMID: 27517637.
      Citations:    
    79. Lin J, Patel SA, Sama AR, Hoffman-Censits JH, Kennedy B, Kilpatrick D, Ye Z, Yang H, Mu Z, Leiby B, Lewis N, Cristofanilli M, Kelly WK. A Phase I/II Study of the Investigational Drug Alisertib in Combination With Abiraterone and Prednisone for Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on Abiraterone. Oncologist. 2016 Nov; 21(11):1296-1297e. PMID: 28178640.
      Citations:    
    80. Kim H, Alshalalfa M, Hoffman-Censits J, Lallas CD, Davicioni E, Lin J, Birbe R, Erho N, Lehrer J, Ashab HA, Takhar M, Olson A, Lam LL, Kelly WK, Knudsen KE, Thangavel C, Seiler R, Feng FY, Schaeffer EM, Trabulsi EJ, Gomella LG, Hurwitz MD, Dicker AP, Den RB. Potential Impact on Clinical Decision Making via a Genome-Wide Expression Profiling: A Case Report. Urol Case Rep. 2016 Nov; 9:51-54. PMID: 27713863.
      Citations:    
    81. Liu D, Plimack ER, Hoffman-Censits J, Garraway LA, Bellmunt J, Van Allen E, Rosenberg JE. Clinical Validation of Chemotherapy Response Biomarker ERCC2 in Muscle-Invasive Urothelial Bladder Carcinoma. JAMA Oncol. 2016 Aug 1; 2(8):1094-6. PMID: 27310333.
      Citations:    
    82. Keefe SM, Hoffman-Censits J, Cohen RB, Mamtani R, Heitjan D, Eliasof S, Nixon A, Turnbull B, Garmey EG, Gunnarsson O, Waliki M, Ciconte J, Jayaraman L, Senderowicz A, Tellez AB, Hennessy M, Piscitelli A, Vaughn D, Smith A, Haas NB. Efficacy of the nanoparticle-drug conjugate CRLX101 in combination with bevacizumab in metastatic renal cell carcinoma: results of an investigator-initiated phase I-IIa clinical trial. Ann Oncol. 2016 Aug; 27(8):1579-85. PMID: 27457310.
      Citations:    
    83. Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A, Dawson N, O'Donnell PH, Balmanoukian A, Loriot Y, Srinivas S, Retz MM, Grivas P, Joseph RW, Galsky MD, Fleming MT, Petrylak DP, Perez-Gracia JL, Burris HA, Castellano D, Canil C, Bellmunt J, Bajorin D, Nickles D, Bourgon R, Frampton GM, Cui N, Mariathasan S, Abidoye O, Fine GD, Dreicer R. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016 May 7; 387(10031):1909-20. PMID: 26952546.
      Citations:    
    84. Plimack ER, Dunbrack RL, Brennan TA, Andrake MD, Zhou Y, Serebriiskii IG, Slifker M, Alpaugh K, Dulaimi E, Palma N, Hoffman-Censits J, Bilusic M, Wong YN, Kutikov A, Viterbo R, Greenberg RE, Chen DY, Lallas CD, Trabulsi EJ, Yelensky R, McConkey DJ, Miller VA, Golemis EA, Ross EA. Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer. Eur Urol. 2015 Dec; 68(6):959-67. PMID: 26238431.
      Citations:    
    85. Hoffman-Censits J, Wong YN. Perioperative and Maintenance Therapy After First-Line Therapy as Paradigms for Drug Discovery in Urothelial Carcinoma. Clin Genitourin Cancer. 2015 Aug; 13(4):302-8. PMID: 25987535.
      Citations:    
    86. Dan TD, Eldredge-Hindy HB, Hoffman-Censits J, Lin J, Kelly WK, Gomella LG, Lallas CD, Trabulsi EJ, Hurwitz MD, Dicker AP, Den RB. Hematologic Toxicity of Concurrent Administration of Radium-223 and Next-generation Antiandrogen Therapies. Am J Clin Oncol. 2015 Feb 25. PMID: 25723740.
      Citations:    
    87. Plimack ER, Hoffman-Censits J, Rosenberg JE, Wong YN, Bellmunt J, Choueiri TK. Reply to d. Pouessel et Al, j.B. Aragon-ching, and B.a. Adesunloye. J Clin Oncol. 2014 Dec 20; 32(36):4171-2. PMID: 25385730.
      Citations:    
    88. Lin J, Zhan T, Duffy D, Hoffman-Censits J, Kilpatrick D, Trabulsi EJ, Lallas CD, Chervoneva I, Limentani K, Kennedy B, Kessler S, Gomella L, Antonarakis ES, Carducci MA, Force T, Kelly WK. A pilot phase II Study of digoxin in patients with recurrent prostate cancer as evident by a rising PSA. Am J Cancer Ther Pharmacol. 2014 Sep 7; 2(1):21-32. PMID: 25580468.
      Citations:    
    89. Plimack ER, Hoffman-Censits JH, Viterbo R, Trabulsi EJ, Ross EA, Greenberg RE, Chen DY, Lallas CD, Wong YN, Lin J, Kutikov A, Dotan E, Brennan TA, Palma N, Dulaimi E, Mehrazin R, Boorjian SA, Kelly WK, Uzzo RG, Hudes GR. Accelerated Methotrexate, Vinblastine, Doxorubicin, and Cisplatin Is Safe, Effective, and Efficient Neoadjuvant Treatment for Muscle-Invasive Bladder Cancer: Results of a Multicenter Phase II Study With Molecular Correlates of Response and Toxicity. J Clin Oncol. 2014 Jun 20; 32(18):1895-901. PMID: 24821881.
      Citations:    
    90. Hoffman-Censits J, Kelly WK. Practical guide to the use of enzalutamide. Can J Urol. 2014 Apr; 21(2 Supp 1):64-9. PMID: 24775726.
      Citations:    
    91. Choi W, Porten S, Kim S, Willis D, Plimack ER, Hoffman-Censits J, Roth B, Cheng T, Tran M, Lee IL, Melquist J, Bondaruk J, Majewski T, Zhang S, Pretzsch S, Baggerly K, Siefker-Radtke A, Czerniak B, Dinney CP, McConkey DJ. Identification of distinct Basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell. 2014 Feb 10; 25(2):152-65. PMID: 24525232.
      Citations:    
    92. Hoffman-Censits J, Fu M. Chemotherapy and targeted therapies: are we making progress in castrate-resistant prostate cancer? Semin Oncol. 2013 Jun; 40(3):361-74. PMID: 23806500.
      Citations:    
    93. Galsky MD, Hendricks R, Svatek R, Bangs R, Hoffman-Censits J, Clement J, Dreicer R, Guancial E, Hahn N, Lerner SP, O'Donnell PH, Quale DZ, Siefker-Radtke A, Shipley W, Sonpavde G, Vaena D, Vinson J, Rosenberg J. Critical analysis of contemporary clinical research in muscle-invasive and metastatic urothelial cancer: A report from the Bladder Cancer Advocacy Network Clinical Trials Working Group. Cancer. 2013 Jun 1; 119(11):1994-8. PMID: 23456777.
      Citations:    
    94. Hoffman-Censits J, Kelly WK. Enzalutamide: a novel antiandrogen for patients with castrate-resistant prostate cancer. Clin Cancer Res. 2013 Mar 15; 19(6):1335-9. PMID: 23300275.
      Citations:    
    95. Beach DF, Somer RA, Hoffman-Censits J, Lin J, Wong YN, Plimack E, Plimeck E, Hudes G, Vaughn D, Bernstein GT, Morris GJ. A wealth of new options: a case presentation of the management of castration-recurrent prostate cancer. Semin Oncol. 2012 Feb; 39(1):1-8. PMID: 22289486.
      Citations:    
    96. Showalter TN, Ohri N, Teti KG, Foley KA, Keith SW, Trabulsi EJ, Lallas CD, Dicker AP, Hoffman-Censits J, Pizzi LT, Gomella LG. Physician beliefs and practices for adjuvant and salvage radiation therapy after prostatectomy. Int J Radiat Oncol Biol Phys. 2012 Feb 1; 82(2):e233-8. PMID: 21605945.
      Citations:    
    97. Gomella LG, Lin J, Hoffman-Censits J, Dugan P, Guiles F, Lallas CD, Singh J, McCue P, Showalter T, Valicenti RK, Dicker A, Trabulsi EJ. Enhancing prostate cancer care through the multidisciplinary clinic approach: a 15-year experience. J Oncol Pract. 2010 Nov; 6(6):e5-e10. PMID: 21358951.
      Citations:    
    98. Trabulsi EJ, Hoffman-Censits J. Chemotherapy for penile and urethral carcinoma. Urol Clin North Am. 2010 Aug; 37(3):467-74. PMID: 20674701.
      Citations:    
    Hoffman-Censits's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (72)
    Explore
    _
    Co-Authors (48)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _
    Physical Neighbors
    _